Parkinson's disease (PD) is the second most common neurodegenerative disorder, with a prevalence of 0.3% in the general population and 1% in people older than 60 years 1 . No neuroprotective treatment for PD exists, but several approaches have been evaluated in clinical trials 2, 3 . Delayed initiation of neuroprotection has been the main reason for the failure of these trials. Approximately 50% of the dopaminergic neurons in the substantia nigra are lost before the initial motor symptoms can be identified 4, 5 . Moreover, according to the widely used Braak staging, Lewy body deposition initiated from the medulla and olfactory bulb occurs much earlier than the development of motor symptoms does 6, 7 . Some prediagnostic symptoms of PD have been reported: rapid eye movement sleep behaviour disorder (RBD), olfactory dysfunction, and constipation occur before the motor symptoms of PD do [8] [9] [10] [11] . However, with the current knowledge of these prediagnostic symptoms, we cannot predict the onset of PD in time to prevent disease progression.
shows the demographics and disease conditions of newly diagnosed anemic patients and nonanemic control patients. Of all the anemic patients (n = 86,334), 75.9% were women and the mean age was 56.4 ± 11.5 yearold. The prevalence of previous or current comorbidity among the anemic patients was 30.1%, 15.5%, 20.8%, and 5.1% for hypertension, diabetes, hyperlipidemia, and gout, respectively. Ibuprofen was prescribed for 25.1% of the anemic patients. After propensity score matching (PSM), the anemic patients and nonanemic controls exhibited nonsignificant differences in all the covariates. Anemia increases PD risk. Within a mean follow-up period of 6.6 years, newly diagnosed anemic patients were at a higher risk of PD than nonanemic controls were, after exclusion of patients who developed PD within 3 years of enrolment. The exclusion was made to prevent biases caused by simultaneous diagnosis of anemia and PD and by PD unmasked by anemia. The incidence rates of PD in the anemic patients and nonanemic controls were 2.38 (95% confidence interval [CI]: 2.20-2.57) and 1.69 (95% CI: 1.56-1.83) per 1,000 person-years, respectively, with an adjusted hazard ratio (aHR) of 1.36 (95% CI: 1.22-1.52, p < 0.001) for the anemic patients ( Fig. 2A) , based on the competing risk regression model. The aHRs for developing PD in the patients with and without iron deficiency anemia (IDA) were 1.49 (95% CI: 1.24-1.79, p < 0.001) and 1.29 (95% CI: 1.12-1.48, p < 0.001), respectively (Fig. 2B,C) . The results obtained from competing risk models for stratified data showed similar significantly increased risk (Supplementary Table S1 ).
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Iron supplementation to IDA patients did not significantly affect PD risk (Fig. 3) . The aHR of developing PD in IDA patients without iron supplementation was 1.86 (95% CI: 1.46-2.35, p < 0.001), and that in IDA patients with more than 28 days of iron supplementation was 1.32 (95% CI: 1.07-1.63, p < 0.01). Similar results were obtained from competing risk models for stratified data (Supplementary Table S2) .
Discussion
The present study demonstrated that newly diagnosed anemic patients might have a higher risk of developing PD 4 or more years after the initial anemia diagnosis. Of all the anemic patients, those with IDA tended to exhibit higher PD risk, which remained unaffected by iron supplementation.
The association between anemia and higher PD risk may not result from anemia alone. For instance, hereditary anemia types, such as sickle cell anemia and thalassemia, have not been identified as risk factors for PD, to the best of our knowledge. By contrast, several factors may account for the aforementioned association, such as oxidative stress, a major cause of PD 14 .
Erythrocytes of PD patients demonstrate reduced superoxide dismutase and glutathione peroxidase activity and increased lipid peroxidation, both of which indicate increased oxidative stress [14] [15] [16] . Similar to the degeneration of dopaminergic neurons in the substantia nigra, erythrocytes exposed to excessive oxidative stress tend to undergo eryptosis, resulting in anemia 17 . The other possible pathogenetic connection between anemia and PD is α -synuclein, another key aetiology of PD. More than 99% of the α -synuclein in human blood originates from erythrocytes 18 , and the α -synuclein oligomer-to-total protein ratio of erythrocytes is higher in PD patients than in controls 19 . Iron can be another crucial factor leading to the association between anemia and PD. Iron deficiency impairs erythropoiesis and enhances eryptosis, resulting in anemia, whereas increased iron deposition is noted in the substantia nigra of PD patients [20] [21] [22] . In addition, increased serum iron levels are associated with decreased PD risk, and high dietary iron intake reduces PD risk 23, 24 . Iron maldistribution (i.e., improper distribution of iron within the body) 25, 26 may account for the iron deficit in the erythropoietic system and iron overload in the substantia nigra. Moreover, iron modulates dopamine synthesis and reuptake: tyrosine hydroxylase, an enzyme responsible for dopamine synthesis, is iron-dependent 27 , and iron deficiency impairs dopamine reuptake in a mouse model 28 .
The cellular vulnerability upon stress may account for the temporal interval between the onsets of anemia and PD. For instance, after exposure to excessive oxidative stress, neurons become more resistant because of their postmitotic characteristics 29 , and the lifespan of erythrocytes is only 120 days. Another possibility is that the onset of motor symptoms is not the most initial presentation of PD. The initiation of PD pathology occurs years before the degeneration of dopaminergic neurons in the substantia nigra 7 . Oxidative stress, accumulation of α -synuclein, and iron maldistribution may cause anemia as well as initiate PD pathology in the brain. The onset of anemia occurs earlier than that of the motor symptoms of PD does, similar to other nonmotor symptoms (such as RBD, anxiety, and constipation), which occur in the prediagnostic stage and precede PD diagnosis by 4-20 years 30 . The strength of this study is that we identified newly diagnosed anemia as a potential biomarker of PD, after excluding anemia caused by chronic renal disease and several temporary blood loss-related anemia types (such as a pre-existing major operation or peptic ulcer); the exclusion enabled us to focus on anemia caused by impaired erythropoiesis and increased eryptosis. Anemia is common in the general population and can be easily detected through minimally invasive blood sampling. Anemia, along with other well-known risk factors for or prediagnostic symptoms of PD, such as RBD, olfactory dysfunction, and severe constipation 11 , can be used in the potential panel of biomarkers for predicting PD in the future. We also excluded patients with a ≤ 3-year interval between anemia and PD diagnoses to reduce the potential biases caused by simultaneous diagnosis of anemia and PD and by PD unmasked by anemia. Through the current approach, we confirmed the hypothesis that newly diagnosed anemia predicts PD risk. Finally, our PSM approach facilitated the selection of controls with baseline characteristics similar to those of our anemic patients for reducing the number of confounding factors.
This study had the following limitations. First, some anemic patients can be asymptomatic and thus not visit the clinic and obtain diagnosis; therefore, the incidence of PD in the nonanemic controls was probably overestimated because of the presence of these asymptomatic patients. Second, anemic patients are more likely to visit clinics; thus, they are more likely to be diagnosed with PD than nonanemic controls are. Third, the accuracy of the diagnosis of PD is of concern. Although Lee et al. had demonstrated that the accuracy of PD diagnosis in the NHIRD is 94.8% 31 , however, the validation was conducted by medical review, which is not the standard way of diagnosing PD in most of studies. The misclassification of PD in National Health Insurance Research Database (NHIRD) by essential tremor or vascular Parkinson'sism may bias the true risk of anemia in developing PD. Considering the degree of misclassification of PD was the same in the anemia and nonanemic groups, it would result in underestimating the risk. Finally, a general limitation for all health insurance database research is the lack of information on some lifestyle risk factors and the raw data of examinations; data regarding factors, such as smoking, coffee consumption, well water consumption, and pesticide exposure, which can significantly affect incidence of PD 32 , were unavailable in the NHIRD and could not be adjusted for in the present study. In addition, unlike a previous study conducted by Savica et al. 13 , which analysed the hemoglobin levels and medical records, the present study relied on anemia diagnoses by clinicians, which may be less sensitive and delayed; nevertheless, this discrepancy in the data acquisition did not generate a conflicting result, further confirming the association between anemia and PD.
In summary, we demonstrated that newly diagnosed anemic patients might have a higher risk of developing PD 4 or more years after the initial anemia diagnosis, indicating the possible association between anemia and PD risk. Oxidative stress, α -synuclein accumulation, and iron deficiency or maldistribution may be the shared etiologies responsible for this association. Further research is warranted to identify the cause-consequence effect of these two disorders.
Methods

Ethics statement. This study was approved by the joint institutional review board of Taipei Medical
University (approval N201509044). Confidentiality was ensured by abiding by data regulations of the Health and Welfare Data Science Center (HWDC), Ministry of Health and Welfare, Executive Yuan, Taiwan. The HWDC releases patient-level data to investigators only for research to protect patient privacy; moreover, the individual identifiers in these data are encrypted before release. Therefore, the requirement for informed consent from the study participants was exempted by the joint institutional review board. All the study methods were in accordance with the guidelines approved by the joint institutional review board and aforementioned governmental regulations. the Anatomical Therapeutic Chemical [ATC] Classification System for Medications), reimbursement amounts, patient demographic information, and patient-and provider-encrypted identifiers. To verify the accuracy of the diagnoses and rationale for treatments, the NHIA routinely samples a portion of the NHI claims, and hospitals and clinics are penalised if they are found to provide unnecessary medical treatments. The purpose of setting this wash-out period is to make sure that all anemia patients were newly diagnosed. We then excluded patients with anemia secondary to blood loss, haemolytic disorders, pancytopenia, and vitamin deficiency-related anemia. In addition, we enrolled only those patients who received at least one blood test service claim within 3 months before the date of anemia diagnosis claim to ensure that the diagnosis of anemia was active. The first date of anemia diagnosis claim was considered the index date of anemia diagnosis. Patients were also excluded if they (1) had hereditary and degenerative diseases of the central nervous system (ICD-9-CM: 330-337) except for PD and psychiatric disorders (ICD-9-CM: 290-295); (2) had traumatic brain injury (ICD-9-CM: 800-804 and 850-854), which increases PD risk 33 ; (3) had a history of PD before the index of anemia; (4) had cerebrovascular diseases (ICD-9-CM: 430-438), which may result in vascular parkinsonism; or (5) had some diseases or medical conditions that are likely to cause anemia, such as gastrointestinal bleeding disorders and chronic renal disease, and underwent major surgery (ICD-9 procedure codes: 01-05, surgery on the nervous system; 30, 32, and 33, surgery on the respiratory system; 35, 36.1-36.9, 37.5, 37.6, 38, and 39, surgery on the cardiovascular system; 40, surgery on the lymphatic system; and 42-54, surgery on the digestive system). An exclusion criterion (5) was used to exclude patients with anemia secondary to blood loss or general medical illness.
Study cohort.
In the present study, the patients without an anemia diagnosis were referred to as nonanemic controls. For each anemic patient, we selected one nonanemic control through PSM, which aided in grouping each case and control with similar baseline characteristics but differences in anemia exposure [34] [35] [36] . PSM is commonly used in observational studies to reduce sample selection bias [37] [38] [39] . In this study, the propensity score was measured on the basis of age, sex, hypertension (ICD-9-CM: 401-405), diabetes (ICD-9-CM: 250), hyperlipidemia (ICD-9-CM: 272), gout (ICD-9-CM: 274), and renal disease (ICD-9-CM: 580-589). Ibuprofen (ATC: M01AE01) was also considered as a medication because it reduces PD risk 40 . Because the controls were nonanemic, they were assigned a date for pseudoanemia, corresponding to the index date of anemia of their matched anemic patients.
Main outcome. The main outcome was PD diagnosis (ICD-9-CM: 332). To ensure the validity of diagnoses, patients with PD were selected only if they received PD medication (ATC: N04A and N04B) within the same visit for diagnosis because these medications confirmed that the disease presented as an active episode. To test the hypothesis that newly diagnosed anemia increases PD risk in the later stages of life, a 3-year window period was introduced between anemia and PD diagnoses, which enabled us to avoid including PD patients with simultaneous anemia and PD diagnoses as well as PD cases unmasked by anemia.
Statistical analysis. The standardised difference was used to compare the mean of continuous and binary variables between anemic patients and matched controls. The standardised difference is a method used to measure the similarity of the baseline characteristics in propensity score-matched samples 34, 36, 38 and represents the difference in the means of two groups in the units of standard deviation. Unlike significance testing, where the convention p < 0.05 denotes statistical significance, standardised differences of < 0.10 likely denote a negligible imbalance between patients and their matched controls 36, 38 . To estimate the risk of anemia and PD in a population-based cohort study with a matched design, a stratified competing risk regression analysis should be applied. This is because the mortality rate of anemic patients is significantly higher that of nonanemic controls (17.75 vs. 9.62 per 1000 person-years). Without considering pre-PD deaths as a competing event, this study would more likely overestimate the association between anemia and PD. Therefore, we limited our analysis to consider only two competing events: PD development and pre-PD deaths; deaths occurring after PD development were not considered in this analysis. The follow-up period was calculated from the index date of anemia or pseudoanemia diagnosis after the completion of a 3-year washout period to (1) the date of PD diagnosis; (2) the date of death based on the Death Record Registry of Taiwan; or (3) December 31, 2013, for both the anemic patients and nonanemic controls not developing PD and pre-PD deaths. Rather than applying the competing risk regression for stratified data newly proposed by Zhou et al. 41 and R package 'crrSC' developed in 2015, we used the 'stcrreg' in the Stata statistical software for estimating the association between anemia and PD. Stata's stcrreg implements competing-risks regression according to Fine and Grey's proportional subhazards model 42 developed in 1999; it has become a regular package in STATA 11. The 'stcrreg' has been applied in numerous studies. By using this statistical package, we can obtain the estimations with no loss of validity, even without using matched analysis 43 . However, the results obtained using the competing risk model for the stratified data-based R package are presented in the Supplementary Data.
Subgroup analysis was conducted to select patients with IDA not secondary to blood loss (ICD-9-CM: 280.1, 280.8, and 280.9) for investigating whether iron connects the etiology of anemia and PD. In our specific group of patients, the effect of substantial iron supplementation (ATC: B03A; > 28 days) was also evaluated. All analyses were performed using SAS/STAT 9.2 (SAS Institute Inc., Cary, NC, USA), STATA 12 (Stata Corp LP, College Station, TX, USA), and R (version 3.2.5 for Windows). A two-sided p value of < 0.05 or a standardised difference of > 0.1 was considered significant.
